Core Insights - Weigao Co., Ltd. reported a revenue of 1.106 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 2.12% [1] - The net profit attributable to shareholders reached 207 million yuan, marking a year-on-year increase of 26.24% [1] - Basic earnings per share stood at 0.52 yuan [1] Revenue and Profit Performance - The company experienced stable execution of bulk procurement in the orthopedic sector during the reporting period [1] - The market share of leading domestic brands in the orthopedic field continued to rise [1] Strategic Initiatives - The company is undergoing a transformation in its sales model, focusing on professional departments for business unit division [1] - This transformation aims to optimize and upgrade the marketing structure, leading to increased specialization and flexibility within the sales team [1] - Enhanced professional service levels in clinical settings have contributed to sustained growth in revenue and sales volume across product lines [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 海外監管公佈 本公佈乃根據香港聯合交易所有限公司證券上市規則第13.10B條之披露規定 作出。根據中華人民共和國之相關規定，山東威高骨科材料有限公司於上海 證券交易所網站(http://www.sse.com.cn/home/search/?webswd=688161)刊發公 佈。 承董事會命 山東威高集團醫用高分子製品股份有限公司 董事長 龍經 二零二五年十月三十日 中國山東省威海市 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * 於本公佈刊發日期，董事會成員包括： 龍 經先生 （執行董事） 叢日楠先生 （執行董事） 盧均強先生 （執行董事） 王道明先生 （執行董事） 陳 林先生 （非執行董事） 湯正鵬先生 （非執行董事） 李國 ...

Core Viewpoint - Multiple companies, including China Feihe and Lianyi Rong Technology, conducted share buybacks on October 24, 2025, with China Feihe leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 5.885 million shares for a total of 23.6977 million yuan, representing 0.087% of its total share capital [2]. - Lianyi Rong Technology (09959) repurchased 2.4 million shares for 7.3782 million yuan, accounting for 3.516% of its total share capital [2]. - Beike-W (02423) repurchased 1.1784 million shares for 7 million yuan, which is 1.722% of its total share capital [2]. Group 2: Other Notable Buybacks - Yum China (09987) repurchased 17,800 shares for 6.2549 million yuan, representing 2.830% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 400,000 shares for 5.7447 million yuan, which is 0.545% of its total share capital [2]. - Kangsong Pharmaceutical (01681) repurchased 100,000 shares for 1.5180 million yuan, accounting for 8.582% of its total share capital [2].

智通财经APP讯，威高股份(01066)发布公告，于2025年10月24日，该公司斥资7.88万港元回购1.4万股股 份，每股回购价格为5.63港元。 ...

威高股份(01066.HK)公告，10月24日耗资7.9万港元回购1.4万股。 ...

威高股份(01066)发布公告，于2025年10月24日，该公司斥资7.88万港元回购1.4万股股份，每股回购价 格为5.63港元。 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年10月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存 ...

Group 1 - Multiple companies conducted share buybacks on October 21, 2025, with a total of 30 companies listed [1] - The largest buyback was by Cloud Factory (N23027), repurchasing 2.1 million shares for a total of 8.22 million yuan [1][2] - Other notable buybacks include Linklogis Technology (W09959) with 2.38 million shares for 7.45 million yuan and Mengniu Dairy (02319) with 500,000 shares for 7.26 million yuan [2] Group 2 - Cumulative buyback amounts for the year show Cloud Factory (N23027) has repurchased a total of 26.62 million shares, representing 5.786% of its total share capital [2] - Linklogis Technology (W09959) has repurchased 67.82 million shares, accounting for 3.174% of its total share capital [2] - Other companies with significant cumulative buybacks include Stone Four Pharmaceutical (02005) with 39.20 million shares (1.328%) and Kangchen Pharmaceutical (01681) with 6.50 million shares (7.637%) [2][3]

Group 1 - The company Weigao Group (01066) announced a share buyback on October 21, 2025, spending HKD 993,900 to repurchase 177,200 shares [1] - The buyback price ranged from HKD 5.59 to HKD 5.62 per share [1]

Core Viewpoint - Weigao Group (01066.HK) announced a share buyback on October 21, spending HKD 994,000 to repurchase 177,000 shares [1] Summary by Category Company Actions - The company executed a buyback of 177,000 shares at a cost of HKD 994,000 on October 21 [1]